1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling

William Somers¹, Mark Stahl and Jasbir S.Seehra

Small Molecule Drug Discovery, Genetics Institute, Inc., 87 Cambridge Park Drive, Cambridge, MA 02140, USA
¹Corresponding author

Interleukin 6 (IL-6) has many biological activities in vivo, and deregulation has been implicated in many disease processes. IL-6, a 185 amino acid polypeptide was refolded, purified and crystallized. The crystals diffracted to beyond 1.9 Å and the structure was solved using single isomorphous replacement. The X-ray structure of IL-6 is composed of a four helix bundle linked by loops and an additional mini-helix. 157 out of 185 residues are well defined in the final structure, with 18 N-terminal and 8 A-B loop amino acids displaying no interpretable electron density. The three-dimensional structure has been used to construct a model of IL-6 interacting with the IL-6 receptor (α-chain) and gp130 (β-chain) that gives new insight into the process of molecular recognition and signaling. Based on this model, we predict a fourth binding site on IL-6, a low affinity IL-6–IL-6 interaction, which may be necessary for the sequential assembly of a functional hexameric IL-6 receptor complex.

Keywords: crystal structure/interleukin 6/receptor/signaling

Introduction

Interleukin 6 (IL-6) is a pleiotropic cytokine with a variety of stimulatory effects on hematopoietic cells and cells of the immune system (Hirano et al., 1986; Wong et al., 1988; Kishimoto et al., 1992). Major cellular targets include B lymphocytes, T lymphocytes, the enhancement of hematopoietic colony formation and the production of acute phase response proteins in the liver (Mackiewicz et al., 1992). IL-6 appears to be a component of the immune system, with knock-out mice exhibiting an impaired IgG and IgA response (Kopf et al., 1994; Ramsay et al., 1994).

Of particular interest is the observation of the involvement of IL-6 in bone homeostasis. In Paget’s disease and in multiple myeloma patients where significant bone loss occurs, a good correlation has been found with increased IL-6 levels. Interestingly, the level of IL-6 is affected by estrogen in bone marrow-derived stromal cells and causes a decrease in the development of osteoclasts (Girasole et al., 1992), while estrogen loss (by mouse ovariectomy) causes enhanced osteoclast development in ex vivo cultures of bone marrow and increased osteoclasts in trabecular bone. Most importantly, osteoclast development was inhibited by the in vivo or in vitro administration of estrogen or neutralizing IL-6 monoclonal antibodies (Jilka et al., 1992). Mutant mice lacking IL-6 have normal amounts of trabecular bone and ovariectomy does not cause bone loss or a change in the rate of remodeling (Poli et al., 1994). These studies strongly suggest that IL-6 plays an important role in post-menopausal bone loss.

IL-6 belongs to a family which share remarkably similar structural features both for the cytokines and the receptors to which they bind. These similarities also extend to the sequential clustering events leading to signal transduction. The closest members of the family include leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M and IL-11 (Yamasaki et al., 1988; Davis et al., 1991; Gearing et al., 1991; Kishimoto et al., 1992, 1994; Miyajima et al., 1992). IL-6 receptor consists of two polypeptides: the α chain (IL-6r), an 80 kDa transmembrane glycoprotein that binds IL-6 with low affinity, and the β chain (gp130), a 130 kDa transmembrane glycoprotein that binds to the IL-6–IL-6r heterodimer to form the high affinity signal transducing complex (Taga et al., 1989).

The IL-6r is a transmembrane protein composed of a cytokine binding type I domain (necessary and sufficient for binding IL-6; Yawata et al., 1993), an Ig-like domain and a short cytosolic domain (Yamasaki et al., 1988) that is not required for signaling (Taga et al., 1989). gp130 is also a transmembrane protein composed of an Ig-like domain, cytokine type I domain, a contactin-like region, a transmembrane domain and a cytosolic domain necessary for signaling, containing a motif known as box1, box2 (Murakami et al., 1991). gp130 is a signal transduction component of not only the IL-6 receptor but also the LIF, CNTF, oncostatin M and the IL-11 receptors (Taga et al., 1992); therefore, the α chain distribution dictates the cellular response (Kishimoto et al., 1992). Signal transduction by IL-6 follows the dimerization of gp130, which activates a bound JAK2 (Argentsinger et al., 1993).

Recently, studies utilizing size exclusion chromatography and equilibrium centrifugation have shown that IL-6 binds to the soluble extracellular domain of IL-6r (sIL-6r) to form a heterodimer (Ward et al., 1994). However, in the presence of the soluble extracellular domain of gp130 (sgp130), a hexameric complex is formed that is composed of IL-6, sIL-6r and sgp130 in a 1:2:2 stoichiometry (Ward et al., 1994). These studies, combined with the evidence from structural, biochemical and mutagenesis studies of the human growth hormone (hGH), human growth hormone receptor (hGHR) and human prolactin receptor (hPRLr) complexes (De Vos et al., 1992; Somers et al., 1994), provide evidence that assembly of the IL-6 signaling complex is an ordered and sequential process.

Analysis of IL-6 site-directed mutagenesis data provides further support for such a structural model. The first class
of IL-6 mutants (site 1) showed reduced binding to IL-6r (Savino et al., 1993). Two additional, distinct classes of IL-6 mutants (sites 2 and 3) have been isolated which bind to IL-6r and yet fail to transduce (Brakenhoff et al., 1994; Ehlers et al., 1994). IL-6 with both site 2 and site 3 mutations not only fails to transduce signal but functions as an antagonist in an IL-6-dependent proliferation assay (Brakenhoff et al., 1994). IL-6r point mutants have also been identified which result in normal IL-6 binding but no signal transduction (Yawata et al., 1993). It has been speculated that these mutations are in a region of IL-6r that is involved in low affinity binding to gp130.

We report here the 1.9 Å X-ray structure of human recombinant IL-6 and compare the structure of IL-6 with known structures of other closely related cytokines. The availability of the three-dimensional structure allows a detailed interpretation of previously reported mutagenesis studies and a better understanding of how they affect IL-6r–gp130 binding. A three-dimensional model of the hexameric IL-6 receptor complex is also presented based upon reported mutagenesis studies, biochemical data and the structure of the hGHr complex. Based on our model, we predict a fourth binding site on IL-6, an IL-6–IL-6 interaction, which may be necessary for the sequential assembly of a functional hexameric IL-6 receptor complex.

Results

Protein structure

The crystal structure of IL-6 (Figure 1) is a four helix bundle with a topology that has now been seen for a number of other cytokines in the superfamily described by Bazan (Bazan, 1990, 1991; Sprang and Bazan, 1993). The four helices are arranged so that the helices A and B run in the same direction and C and D in the opposite direction. Linking the helices in this arrangement is made possible by a long loop joining the A and B helices, a short one between B and C and finally a second long connection between C and the fourth main helix D.

Backbone structure

The N-terminal 18 amino acids of IL-6 are not visible in electron density maps and consequently have not been modeled. The first long helix (A) extends from Ser21 to Ala45 and is connected to helix B by a 25 amino acid loop. The first structural feature of the inter-helix connection is a loop formed by a disulfide bond between cysteines 44 and 50. Cys50 is poorly ordered and precedes an eight-residue break with no interpretable electron density. This break is followed by Ala61–Glu69 in an extended conformation which presents the hydrophobic side chains of Leu62, Leu64, Phe65 and Met67 into a cleft between helices B and D. Before the start of helix B, the final section of the loop is defined by three structural elements, a type I β turn (Ala68–Asp71), a disulfide (Cys73–Cys83) and a type II β turn (Gln75–Phe78).

Helix B (Glu80–Gln102) has an average φ,ψ torsion angles of −63.8° and −39.5°. The φ,ψ values for Glu93 and Phe94 are −64.5°, −25.6° and −76.8°, −16.5° respectively, caused by a 38° bend in the direction of the helix axis centered at these residues. This bend results in a break in the α-helical hydrogen bonding pattern, such that Leu92 O is hydrogen-bonded to Val96 N via water 19. The short cross-over connection between helices B and C extends from Asn103 to Ser108 and has higher than average B-factors (37.9 Å²).

Helix C (Glu109–Lys129) is followed by the second long cross-over connection. Residues Leu133–Asp140 are in an extended conformation interacting with helix B via the hydrophobic side chains of Leu133, Ile136 and Pro139. Following this there is an additional short helix (E) lying outside the main four helical bundle. The three turns of this helix are formed by amino acids from Pro141 to Gln152.

Residues Gln156–Arg182 form the final D helix. Located at the N-terminus of this helix is the only tryptophan (157) in IL-6. In solution, this tryptophan would be solvent exposed but in the crystal is buried in a hydrophobic pocket made by two symmetry-related molecules. The two C-terminal residues of IL-6, Gln183 and Met184, have higher than average B-factors (35.8 Å²) but good electron density.

Side chain contacts

The relative disposition of the four main helices of IL-6 is maintained by a network of hydrophobic interactions in the core of the molecule. These interactions occur in layers of residues down the entire axis of the bundle. The lower end of the core (Figure 1) is capped by a hydrogen bond between the side chains of Lys129 and Ser22 and hydrophobic interactions between Leu84 and Met184. The core residues are Ile25, Ile29, Ile32, Ile36, Leu39, Thr43, Ile87, Leu91, Leu98, Leu101, Phe105, Ala112, Val115, Thr119, Leu122, Leu126, Thr163, Leu167, Phe170, Leu174, Ser177 and Leu181. This core is terminated at the other end by a hydrogen bond between Ser108 and Glu42. Side chains in the core that are capable of forming hydrogen bonds make interactions away from the center.
Thr43 Oγ interacts with an ordered water, Thr119 Oγ donates a hydrogen bond to Val115 O, Thr163 Oγ donates a hydrogen bond to Gln159 O and Ser177 Oγ donates to Phe173 O. On the outside of this main hydrophobic core lies a cluster of hydrophobic side chains stabilizing the position of the E mini-helix. This mini-helix presents the side chains of three leucines (147,148,151) towards the hydrophobic side chains of helix B (Val96, Tyr97, Tyr100), helix D (Thr162) and the A–B loop (Leu62).

In contrast to the large number of hydrophobic interactions stabilizing the fold of IL-6, only three hydrogen bonds bridge the main helices. Indeed, helix A has no hydrogen bonds with the other helices. Helices B and C interact via a hydrogen bond between the Oe1 of Glu95 and Nζ of Lys120 (2.5 Å). The only other two hydrogen bonds between helices B and D are formed by Arg104 Nη2 to Asp160 Oδ1 (3.0 Å) and Tyr100 Oη to Gln159 Nε2 (2.8 Å). In addition, there is a considerable network of indirect hydrogen bonds via networks of ordered water molecules (described below).

The crystal structure of IL-6 shows that the side chains of Asp26, Arg30 and Met117 each exist in two discrete conformations. The Asp and Arg residues interact with each other and are next to a crystallographic 2-fold axis. In one state, Arg30 donates a hydrogen bond (2.8 Å) from the Ne to Oδ1 of Asp26 (χ1 = −174°). In the second state, rotation of χ torsion angles (Asp26 χ1 = −73°) breaks this hydrogen bond so the arginine now donates a hydrogen bond to water 34 (2.8 Å) and Asp26 hydrogen bonds to water 55 (2.6 Å). In the first conformation, Arg30 interacts with itself and makes a close contact to Asp26 (1.7 Å) through the crystallographic 2-fold axis so that adjacent molecules require the second conformation.

Trp157 which lies at the N-terminal end of helix D is almost completely exposed side from contacts (3.5 Å) with the Ce of Met49. Despite being solvent exposed, this tryptophan is highly ordered through its interactions with a symmetry-related molecule and penetrates deep into a hydrophobic pocket created by the side chains of helices A (Tyr31 and Gly35) and C (Ala114, Val115 and Ser118). The solvent accessibility of the tryptophan is consistent with the fluorescence emission spectra with ελmax ~336 nm (data not shown).

**Ordered water**

The current model of IL-6 contains 121 ordered water molecules, of which 105 have temperature factors ranging from 15.4 to 50.0 Å² (16 water molecules have temperature factors >50.0 Å²). There are only nine water molecules in the second shell which do not interact directly with protein. The ordered water molecules are not distributed uniformly over the entire surface of IL-6 but are localized to clefts in the surface. These water molecules form networks of hydrogen bonds that link the helices and loops that stabilize the crystal structure. One water molecule (47) is completely buried between helices B and C and bridges the two helices by forming hydrogen bonds to the carbonyl oxygens of Ala112 (2.8 Å) and Leu98 (3.0 Å).

The highest density of water is found in the region between the C-terminal regions of helix D and the A–B loop (Figure 2). There are 18 water molecules and two sulfates in this region that form a network of hydrogen bonds linking these two secondary structural elements. From modeling studies described later, this region may be involved in binding to the IL-6r.

**Small molecule binding**

The crystal structure of IL-6 has a single L(+)-tartaric acid molecule bound on a crystallographic 2-fold axis giving a stoichiometry of one tartrate bound to two molecules of IL-6. The binding is mediated by direct hydrogen bonds from Arg182 Ne (2.8 Å) and Nη2 (2.7 Å) to one carboxyl group of tartrate. The same carboxyl atoms hydrogen-bond with Arg179 Ne (2.8 Å) and water 6 (3.0 Å). In addition, the α-OH of tartrate accepts a hydrogen bond from Arg179 Nη2 (3.0 Å) and the β-OH donates a hydrogen bond to the O of Gln175 (2.8 Å). Since the tartrate lies on a crystallographic 2-fold axis,
these interactions are duplicated on the other half of the tartrate from a symmetry-related molecule satisfying almost every possible hydrogen bond.

**Structural comparison of IL-6 with G-CSF and hGH**

The four helix bundle up-up-down-down topology of the helices seen in the structure of IL-6 was predicted by Bazan (Bazan, 1990, 1991; Sprang and Bazan, 1993) to be a common structural fold for cytokines. Although the members of the superfamily share low homology at the amino acid level, the three-dimensional structures of several cytokines reveal a remarkable similarity. Granulocyte colony-stimulating factor (G-CSF), with 16% amino acid sequence identity, is the closest member of the superfamily for which a three-dimensional structure is available (Bazan, 1991). The structures of human G-CSF (hG-CSF; Hill et al., 1993), canine G-CSF and bovine G-CSF (Lovejoy et al., 1993) have all been determined to high resolution. hG-CSF, with the most ordered residues, has been chosen for a detailed comparison with IL-6. hG-CSF shares only 9% amino acid sequence identity with IL-6. hG-CSF has been examined crystallographically in complex with the extracellular domain of its receptor (De Vos et al., 1992) so that a comparison with IL-6 gives insights into the interaction of IL-6 with its receptor (IL-6r) and gp130.

The superposition of G-CSF (Figure 3) on IL-6 using 88 Cα atoms in the helices gives an agreement of 1.1 Å root-mean-square (r.m.s.) between the two structures. For the more distantly related hGH, the agreement is only 1.4 Å r.m.s. over 83 atoms. This superposition reveals a good agreement in both the inter-helix angles and length of helices in these cytokines. However, a close examination reveals significant differences in several regions. The N-termini of IL-6 and G-CSF are disordered so that the crystal structures of both begin at the start of helix A, whereas the N-terminal residues of hGH are ordered and are involved in receptor binding. Helix A is the same length for all three cytokines but does not superimpose well at the C-terminal end. The largest differences at the C-terminal end of this helix are seen for hGH, which may be influenced by the position of the short loop between helices B and C. Following helix A, the first long loop exhibits considerable conformational variability. The disulfide bonds in G-CSF and IL-6 in this region stabilize a very similar conformation for the A–B loop immediately after helix A. However, immediately following this, IL-6 is disordered while the other cytokines have short helical segments. The final part of the loop has the second conserved disulfide which constrains IL-6 and G-CSF to adopt very similar conformations whereas hGH has a second short helix (Figure 3).

Helix B superimposes well at the N-terminus for all three cytokines. IL-6 and hGH both have kinks in the same position in helix B due to a break in the hydrogen bonding and continue to superimpose well after this point. G-CSF does not have this break and extends for another turn. The short loop that connects helices B and C has a different conformation in each case, while hGH includes a three residue insertion, which allows the loop to extend much closer to helix A.

Helix C superimposes well for all three cytokines except in hGH, where it is four residues shorter at the N-terminus. The long loop following helix C is well ordered in IL-6 but lacks residues present in the other two cytokines. At the end of this loop, IL-6 has a helical segment while G-CSF has a short segment of extended conformation. The final long helix (D) is the same length for each structure but does not superimpose well for hGH, which has 10 additional residues extending beyond the C-termini of the other two cytokines.

**Discussion**

IL-6 is a member of the four helix bundle cytokine superfamily which share structural similarities and may share common modes of receptor engagement and activation. These similarities enable signaling models to be constructed that account for the available mutagenesis data. The crystal structure of hGH bound to two molecules of hGHr (De Vos et al., 1992) has provided a useful model for the activation of cytokine receptors upon ligand binding. hGH initially binds an hGHr via a high affinity site on the surface of the cytokine. This dimer of one hGH and one hGHr then binds to a second hGHr. The binding site for the second hGHr is made up of a combination of two low affinity sites: one on the surface of hGH and a site in the C-terminal domain of the first bound receptor. This combination of high and low affinity sites on the surface of hGH ensures that the clustering of hGHr molecules, leading to signaling, is an ordered event.

IL-6-mediated signal transduction has been shown to occur through clustering of two gp130 receptors by IL-6 (Murakami et al., 1993) or an agonistic anti-gp130 monoclonal antibody (Wijdenes et al., 1995). IL-6 binds to a single molecule of IL-6r and forms a heterodimer. In an analogous manner to hGH signaling, this heterodimer is capable of binding to gp130 to form a heterotrimer (IL-6, IL-6r and gp130) with 1:1:1 stoichiometry. Since signaling has been demonstrated to occur through clustering of gp130 molecules, an additional binding step is necessary. Indeed, ultracentrifugation experiments with soluble IL-6, IL-6r and gp130 give a hexamer composed of two molecules of each component (Ward et al., 1994), providing support for an additional clustering event.

Recently, Paonessa and co-workers (Paonessa et al., 1995) presented a model of such a hexamer which was based on a model of IL-6, the hGHr complex (De Vos et al., 1992) and information from biochemical studies. We present a more detailed model of the signaling complex based on the high resolution structure of IL-6 in Figure 4A. This model can be used to rationalize the mutagenesis studies of IL-6.

The first event in signal transduction is the binding of soluble IL-6 through site 1 to IL-6r, forming a heterodimer. The second event is the binding of this heterodimer to gp130 on the cell surface. This binding event is mediated through site 2 on IL-6 interacting with gp130 as well as contacts between the C-terminal domains of IL-6r and gp130. The third event to take place in IL-6 signaling is the binding of two hetero-trimeric complexes mediated by interactions in sites 3 (IL-6rimer 1·gp130 rimer 2) and 4 (IL-6rimer 1·IL-6rimer 2). This model also predicts the possibility of additional interactions between different trimers via the C-terminal halves of the cytokine-binding domains of IL-6r and gp130.
Numerous mutagenesis studies have been performed on IL-6 in an effort to define the receptor binding sites (Fiorillo et al., 1992; Fontaine et al., 1993; Savino et al., 1993, 1994b; Ehlers et al., 1994; Hammacher et al., 1994; de Hon et al., 1995; Ehlers et al., 1995). The data from these mutagenesis studies are re-examined in light of the high resolution crystal structure of IL-6 and are represented as space-filling side chains in Figure 4B.

Site 1 mutants discussed by Savino and co-workers (Savino et al., 1993) are consistent with the hexamer model and map to a region on hGH found to be essential for hGHr binding (Cunningham and Wells, 1989).
two most important binding determinants on hGHr for hGH were found to be tryptophans 104 and 169 (Clackson and Wells, 1995). These tryptophans are inserted into pockets created by mutationally sensitive hGH residues. After superimposition of IL-6 onto hGH in the receptor complex, it is found that these tryptophans from hGHr are inserted into a cleft on the surface of IL-6 (Figure 5). A sequence alignment of receptors shows that IL-6r does not have equivalent tryptophans but may use other large or aromatic residues to bind to the surface of IL-6. The importance of this cleft in the surface of IL-6 is demonstrated by the fact that mutants that affect binding of IL-6r all map to this region (Figures 4B and 5). Consistent with this model, a 100-fold decrease in activity is observed upon mutation of Arg179 to Ala (Fontaine et al., 1993). Mutation of Gln175 to Ala results in a 5-fold decrease in activity (Savino et al., 1993). Interestingly, replacement of Ser176 with Arg causes a 4-fold increase in the activity of IL-6 (Savino et al., 1993). The equivalent residue in hGH is Lys172 which forms the pocket that accepts the tryptophan from hGHr. Arg182 (Lutticken et al., 1991) and Phe74 also form the sides of the cleft and are mutationally sensitive (G.Ciliberto, personal communication). Other mutations in this region which affect binding, Ser177, Ala180, Leu178 and Leu181, are all buried and may be affecting activity by altering the local conformation of IL-6. This region is also the location of the highest density of ordered water molecules (Figure 2) which may play a role in binding receptor by adding entropy to the system as they are displaced.

Site 2 mutations, which bind normally to IL-6 but have reduced affinity for binding to the first molecule of gp130 (Savino et al., 1994a,b), are also consistent with the hexamer model. These mutations are localized to a region on helices A and C and consist of Tyr31→Asp, Gly35→Phe, Ser118→Arg and Val121→Asp (Figure 4B). All are exposed and, with the exception of Gly35, close to site 2 used by IL-6 binding to gp130 in the hexamer model. The reduction in activity observed by the mutation of Gly35 to Phe may be due to indirect longer range effects resulting from the insertion of a large hydrophobic side chain.

In addition to the mutations described above, a chimera consisting of human IL-6 with murine residues 43–55 has
reduced signalling activity but unaltered affinity for IL-6r (Ehlers et al., 1994). Examination of the hexamer model suggests that this region of IL-6 is important for interaction with the second molecule of gp130 via site 3. Other mutants consistent with site 3 in the hexamer model are located at the N-terminus of helix D. Trp157→Arg and Asp160→Arg (Paonessa et al., 1995) are both exposed and able to interact directly with the second gp130 receptor in this model (Figure 4B). The other residues in this region [Gln159→Glu and Thr162→Pro/Thr162→Asp (Brakenhoff et al., 1994; de Hon et al., 1995)] are both buried and consequently may affect gp130 binding indirectly.

Our model predicts additional interactions between two molecules of IL-6 which stabilize the signaling complex. Based on this model, we predict that the region Gln106–Arg113 on IL-6 would interact with the same residues on an adjacent IL-6 across a local 2-fold axis of rotation. The details of these interactions are currently the subject of further investigation.

The structure of IL-6 has allowed further refinement of the hexameric model presented by Paonessa et al. (1995) and has enabled a more detailed understanding of the available mutagenesis data. Since LIF, CNTF, oncostatin M and IL-11 all share gp130 as a common signal transducer and are predicted to have similar four helical structures, the pattern of systematic absences on rotation images clearly indicated it seems likely that a hexameric complex may be a common feature of signal transduction for this family of cytokines.

### Table I. IL-6 data reduction and phasing statistics for a native crystal and single derivative

<table>
<thead>
<tr>
<th></th>
<th>Native</th>
<th>Derivative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolution</td>
<td>10.0–1.9 Å</td>
<td>10.0–2.4 Å</td>
</tr>
<tr>
<td>Number of observations</td>
<td>100,519</td>
<td>31,588</td>
</tr>
<tr>
<td>Number of unique reflections</td>
<td>14,002</td>
<td>7,203</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>97.6</td>
<td>99.1</td>
</tr>
<tr>
<td>Reflections with I/H &gt; 3σ (%)</td>
<td>93.0</td>
<td>95.1</td>
</tr>
<tr>
<td>R-merge (%)</td>
<td>0.031</td>
<td>0.029</td>
</tr>
<tr>
<td>Fractional isomorphous difference (%)</td>
<td>0.264</td>
<td>0.264</td>
</tr>
<tr>
<td>Cullis R-factor (fracentric/centric)</td>
<td>0.57, 0.53</td>
<td>0.57, 0.53</td>
</tr>
<tr>
<td>Phasing power (fracentric/centric)</td>
<td>2.27, 1.84</td>
<td>2.27, 1.84</td>
</tr>
<tr>
<td>Figure of merit</td>
<td>0.57</td>
<td></td>
</tr>
</tbody>
</table>

*Number of observations after pairing partial reflections in adjacent images.

R-merge = \(\sum_{i,j} |I_{ij} - \langle I\rangle| / \sum I\rangle\), where \(I\rangle\) is the intensity of a measured observation and \(\langle I\rangle\) is the average of all symmetry equivalents of that observation.

Fractional isomorphous difference = \(\Sigma |F_{pH} - \langle F_p\rangle| / \Sigma |F_p|\), where \(F_p\) is the native structure factor amplitude and \(F_{pH}\) that of the derivative.

Cullis R-factor is the lack of closure residual/isomorphous difference.

Phasing power = r.m.s. \(F_p\)/lack of closure, where \(F_{HI}\) is the calculated heavy atom contribution.

Intensity data were collected using a Rigaku R-Axis II image plate on a RU-200 X-ray generator running at 5 kW with mirror focusing optics. Examination of the symmetry of reduced rotation data and the pattern of systematic absences on rotation images clearly indicated crystals were of space group P3121 or P3221 with cell parameters a = 49.7 Å and c = 122.0 Å. All high resolution data sets were collected at –168°C on crystals soaked in 20% glycerol as a cryoprotectant. These crystals were found to be highly ordered, diffracting to beyond 1.9 Å resolution. The image plate data were processed with DENZO (Otwinowski, 1993) then scaled with ROTAVATA and AGROVATA (Collaborative Computing Project number 4, 1994) giving the statistics listed in Table I. The structure was solved using single isomorphous replacement with anomalous scattering (SIRAS) prepared by soaking the crystal in 1 mM potassium tetrachloroaurate(III) for 24 h at 4°C. The gold heavy atom derivative gave a single site located using isomorphous difference Pattersons and then confirmed with a clear signal in the anomalous difference Patterson. Refinement of the heavy atom occupancy, position and isotropic thermal parameters followed by calculation of phases was

**Materials and methods**

Recombinant IL-6 expressed in *Escherichia coli* was refolded (Arcone et al., 1991) and purified with ion exchange and hydrophobic interaction chromatography. Purified IL-6 at 15 mg/ml was crystallized using hanging drop vapor diffusion from 1.8 M ammonium sulfate, 300 mM sodium potassium tartrate, in 100 mM pH 6.3 sodium citrate buffer. The largest crystals measured 0.6 x 0.4 x 0.2 mm and took up to 2 months to grow at 4°C.
performed using MLPHARE (Otwinowski, 1991) as part of the CCP4 suite of programs (Collaborative Computing Project number 4, 1994). The phasing statistics reported by MLPHARE are shown in Table I.

Space group ambiguity was resolved by examining 2.8 Å electron density maps phased including the anomalous data. Space group P3121 given a clear protein-ligand boundary with conformational density that corresponded well with the secondary structural elements of the related cytokine β-CSF (Hill et al., 1993). The related space group P3221 gave no recognizable protein features. Electron density was improved further with solvent flattening (Wang, 1985) giving high quality 2.8 Å maps (Figure 6) that were used to build an initial model using QUANTA (Biosym/Molecular Simulations, San Diego, CA) and O (Jones et al., 1991). The model and electron density maps were improved with repeated rounds of least-squares refinement using PROLSQ (Hendrickson, 1985), SIGMAA weighting (Read, 1986) and phase combination at 2.4 Å. Prior antagonist on human myeloma cells.

R maintained so that at the end of refinement these reflections represent a receptor binding. The phasing statistics reported by MLPHARE are shown in Table I. de Hon,F.D. (Biosym/Molecular Simulations, San Diego, CA) and O (Jones et al., 1991) with solvent flattening (Wang, 1985) giving high quality 2.8 Å maps. Liu,J., Wollmer,A. and Rose-John,S. (1994) Identification of two novel CSF (Hill, 1992) structures.


Received on August 26, 1996; revised on October 14, 1996.